Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
08:00am, Monday, 25'th Aug 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, A
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
10:40am, Friday, 22'nd Aug 2025
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Thursday, 14'th Aug 2025
After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
10:40am, Wednesday, 06'th Aug 2025
Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
11:41am, Thursday, 31'st Jul 2025
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
02:06pm, Wednesday, 30'th Jul 2025
Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter
Amarin Reports Second Quarter 2025 Financial Results
07:00am, Wednesday, 30'th Jul 2025
-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Mo
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
01:10pm, Thursday, 24'th Jul 2025
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
07:30am, Wednesday, 23'rd Jul 2025
DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members o
3 Strong Buy Breakout Stocks for Explosive Returns
04:01pm, Thursday, 17'th Jul 2025
MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
10:11am, Monday, 14'th Jul 2025
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
10:40am, Wednesday, 02'nd Jul 2025
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
Best Momentum Stock to Buy for June 27th
11:00am, Friday, 27'th Jun 2025
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
12:10pm, Wednesday, 25'th Jun 2025
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
10:31am, Wednesday, 25'th Jun 2025
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
